FDA Calls Out Amgen Over Misleading Anemia Drug Claims
Direct mailers from Amgen Inc. oversold the benefits of anemia drug Aranesp and omitted important information about its potential to cause heart attacks and strokes, according to a U.S. Food and...To view the full article, register now.
Already a subscriber? Click here to view full article